Darrin Smith
Known title: Executive VP, CIO & SecretaryCIK: 0002104848
Associated companies
Transaction History
| SBRA | ▲ Buy | Grant | 495 | $0 | 8/31/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 501 | $0 | 5/29/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 478 | $0 | 2/27/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 5,483 | $0 | 2/10/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 2,927 | $56K | 2/10/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 14,088 | $0 | 2/10/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 6,390 | $122K | 2/10/2026 | View on chart |
| SBRA | ▲ Buy | Grant | 13,710 | $0 | 1/8/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 5,432 | $107K | 1/8/2026 | View on chart |
| SBRA | ▼ Sell | Tax Withholding | 4,963 | $97K | 1/8/2026 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 14, 2026
Sabra Health Care REIT analysts lower price targets
UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.
Sabra Health Care REIT analysts lower price targets. UBS kept a neutral rating on Sabra Health Care REIT but reduced its price target to $20. Barclays also maintained an equal‑weight stance while cutting its target to $21. Both revisions suggest a more modest outlook for the REIT. The new targets sit near the stock’s recent support level around $19.70.